A phase I dose-finding design with incorporation of historical information and adaptive shrinking boundaries

Although many novel phase I designs have been developed in recent years, few studies have discussed how to incorporate external information into dose-finding designs. In this paper, we first propose a new method for developing a phase I design, Bayesian optimal interval design (BOIN)[Liu S et al. (2015), Yuan Y et al. (2016)], for formally incorporating historical information. An algorithm to automatically generate parameters for prior set-up is introduced. Second, we propose a method to relax the fixed boundaries of the BOIN design to be adaptive, such that the accumulative information can be used more appropriately. This modified design is called adaptive BOIN (aBOIN). Simulation studies to examine performances of the aBOIN design in small and large sample sizes revealed comparable performances for the aBOIN and original BOIN designs for small sample sizes. However, aBOIN outperformed BOIN in moderate sample sizes. Simulation results also showed that when historical trials are conducted in settings similar to those for the current trial, their performance can be significantly improved. This approach can be applied directly to pediatric cancer trials, since all phase I trials in children are followed by similar efficient adult trials in the current drug development paradigm. However, when information is weak, operating characteristics are compromised.